Completed
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
NCT03553823
- Conditions
- Chronic Plaque-type Psoriasis, Pathological Conditions, Signs and Symptoms, Pruritus, +6 more
- Locations
-
- Novartis Investigative Site New Orleans, Louisiana, United States
- Novartis Investigative Site East Windsor, New Jersey, United States
- Novartis Investigative Site Philadelphia, Pennsylvania, United States
- Novartis Investigative Site Dallas, Texas, United States